SEC Form 4 · accession 0001127602-17-013092
AMGEN INC · AMGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert A Bradway
Officer — Chairman, CEO and President · Director
Period of report
Mar 24, 2017
Accepted (ET)
Mar 28, 2017 · 6:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000318154
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Mar 24, 2017 | F | 36,384 | $166.04 | D | 381,482 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 5,145 RSUs which vest on 1/31/2018; 8,977 RSUs which vest in two installments of 4,421 and 4,556 on 1/30/2018 and 1/30/2019, respectively; and 14,070 RSUs which vest in two equal installments of 4,643 on 5/3/2018 and 5/3/2019 and one installment of 4,784 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
- F2These shares include 1,230 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.